Navigation Links
NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
Date:3/17/2008

ANN ARBOR, Mich., March 17 /PRNewswire/ -- NanoBio Corporation reported top-level findings today from its phase 2b study of NB-001, a topical lotion to treat herpes labialis (cold sores). The randomized, double-blind, vehicle- controlled study met its primary and secondary endpoints by demonstrating clear efficacy and safety in 482 patients.

NanoBio's uniquely formulated lotion resulted in faster healing of cold sores, at a rate never seen before by a topical product. The company's targeted phase 3 dose demonstrated highly statistically significant clinical efficacy in phase 2b at a magnitude comparable with or superior to what has been reported for the leading oral (systemic) anti-herpetic drugs on the market today.

Additionally, NB-001 demonstrated an excellent safety profile, with no serious adverse events, significant skin irritation or systemic blood absorption. In contrast, leading oral systemic treatments for herpes labialis carry label warnings that include nausea, diarrhea, vomiting, rash and migraine.

"Through this trial, we have confirmed that NB-001 achieves the efficacy of leading systemic treatments without presenting safety, drug interaction or toxicity risks," said James R. Baker Jr., MD, founder and chairman of NanoBio Corporation. "Based on the data, NanoBio will move immediately to initiate plans to begin phase 3 testing of NB-001 in early 2009." The full data set from the phase 2b study will be presented following a standard peer review process.

NB-001 is a proprietary oil-in-water emulsion composed of nanometer-sized droplets that employ a physical process to disrupt the outer lipid membrane of viruses. The droplets traverse the pores and hair follicles of the skin without disrupting normal tissues. These droplets accumulate in the epidermis and dermis where they interact directly with and kill the viral organisms at the site of infection.

"The product's novel mechanism leaves little risk of drug resistance, which is a concern with the systemic antiviral therapies used to treat herpes labialis," said Baker. "This attribute coupled with its safety profile may eventually allow NB-001 to be sold without a prescription. This will be important to those people affected by this disease, since the vast majority of herpes labialis sufferers today seek over-the-counter treatments for their cold sores."

NanoBio's pipeline of topical anti-infective products and nasally delivered vaccines are based on the company's novel NanoStat technology, a platform protected by five issued patents, as well as numerous pending filings. The issued patents provide patent protection through 2019, while pending filings would extend protection through 2029.

About NanoBio

NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.


'/>"/>
SOURCE NanoBio Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
2. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
3. Synbiotics Corporation Announces Human Submission for FluDetect(R)
4. Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
5. CEL-SCI Corporation Reports First Quarter Financial Results
6. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
7. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
8. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
9. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
10. CEL-SCI Corporation Announces 2007 Financial Results
11. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
(Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
Breaking Medicine News(10 mins):